Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xtandi
Pharma
Pfizer details survival win in bid for broad prostate cancer nod
Pfizer hopes a unique life-extension benefit for Talzenna can serve to further expand the drug's already broadest-in-class prostate cancer label.
Angus Liu
Feb 13, 2025 10:00am
Pfizer targets broad Talzenna label in prostate cancer
Oct 10, 2024 10:18am
J&J's Erleada shows survival edge over Xtandi in real-world study
Oct 2, 2024 2:42pm
Pfizer sees 8 blockbuster cancer drugs from each focus area
Jun 13, 2024 12:45pm
EU regulator signs off on Novo's weekly insulin and other meds
Mar 22, 2024 11:39am
Lawmakers blast Biden administration's 'march-in' proposal
Feb 23, 2024 9:53am
